Veille Pharma
20.5K views | +0 today
Veille Pharma
Chargé d'affaires chez Patientsworld. Mes posts n'engagent que moi.
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

Yasmin, Yaz, Angeliq and Risk for Blood Clots

Yasmin, Yaz, Angeliq and Risk for Blood Clots | Veille Pharma | Scoop.it

Birth control pills, patches and rings typically contain an estrogen and a progestin component. It has long been known that estrogen-containing birth control preparations (pill, patch, ring) increase the risk for blood clots (DVT, PE). This risk is partially due to the estrogen. However, part of the risk for clots is also due to the type of progestin in these preparations. This first became clear when it was found that so-called 3rd generation contraceptives (those containing the progestin called desogestrel) have about two times higher a risk for DVT and PE that so-called 2nd generation pills.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Le complexe prothrombinique Cofact : un antidote au rivaroxaban ?

Le complexe prothrombinique Cofact : un antidote au rivaroxaban ? | Veille Pharma | Scoop.it

L’absence d’antidote en cas d'hémorragie grave ou en cas de nécessité d’un geste invasif en urgence chez les patients traités par les nouveaux anticoagulants est un problème fréquemment soulevé.
L’effet inhibiteur de l’effet anticoagulant d’un complexe prothrombinique non activé, le Cofact® , sur le dabigatran et le rivaroxaban a été évalué dans une étude randomisée, en double aveugle, contrôlée contre placebo. 12 volontaires sains de sexe masculin ont reçu du rivaroxaban 20 mg deux fois par jour (n = 6) ou du dabigatran 150 mg deux fois par jour (n = 6) pendant 2,5 jours, puis un bolus de 50 UI / kg d’un complexe prothrombinique, le Cofact, ou un volume similaire de solution saline.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

FDA Approves Watson Pharmaceuticals Generic Lovenox (Enoxaparin)

The FDA has granted approval to Amphastar’s generic version of Lovenox (enoxaparin sodium), Watson Pharmaceuticals has announced. The low molecular weight heparin will be sold by Watson under an arrangement with Amphastar.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Le ministère de la santé Japonais demande au groupe Boehringer Ingelheim d’apposer des warning sur le risque d’hémorragie fatale sous l’anticoagulant de nouvelle génération Pradaxa | Pharmactua

Le ministère de la santé Japonais demande au groupe Boehringer Ingelheim d’apposer des warning sur le risque d’hémorragie fatale sous l’anticoagulant de nouvelle génération Pradaxa | Pharmactua | Veille Pharma | Scoop.it

Le ministère de la santé Japonais demande au groupe Boehringer Ingelheim d’apposer des warning sur le risque d’hémorragie fatale sous l’anticoagulant de nouvelle génération Pradaxa. Le ministère de la santé du Japon a rapporté entre le 14 mars et le 11 aout 2011, 1181 cas d’hémorragies, principalement digestives sous Pradaxa, (dabigatran) sur un total de 64.000 patients traités. 5 cas d’hémorragies fatales ont été rapportés sur la période.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Medical News: DVT Risk Starts Early, Stays Long After Stroke

Medical News: DVT Risk Starts Early, Stays Long After Stroke | Veille Pharma | Scoop.it

The risk for deep vein thrombosis among patients immobilized by a stroke hits hardest soon after the event, but lingers on for at least a month, researchers found.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Pfizer/BMS clot drug expected to best Pradaxa, Xarelto - FiercePharma

Look out, warfarin-alternative market. Eliquis may be the last to hit, but it may hit the hardest. Some much-anticipated data came out at the European Society of Cardiology conference over the weekend, showing the Pfizer/Bristol-Myers Squibb drug beat standard warfarin therapy at reducing stroke or systemic embolism in patients with atrial fibrillation--with less risk of bleeding to boot. Plus, the risk of death from any cause was cut by 11%, a statistically significant result that's sure to make it into Eliquis' marketing campaigns.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Physicians Weigh in on Pradaxa (dabigatran), Xarelto (rivaroxaban) and Apixaban

Physicians Weigh in on Pradaxa (dabigatran), Xarelto (rivaroxaban) and Apixaban | Veille Pharma | Scoop.it
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Comment surveiller l'effet des nouveaux anticoagulants, si besoin était ?

Paris, France - La fin programmée des AVK, et ainsi, de la surveillance de la coagulation dans des indications majeures, est une révolution qui n'ira peut-être pas jusqu'au bout : au fur et à mesure que l'indication des nouveaux anticoagulants monte en puissance, des cas apparaissent, où, manifestement, une surveillance biologique aurait été souhaitable. Ces situations seront probablement rares ; il faut néanmoins s'y préparer, et pour commencer, ne pas se tromper dans des interprétations tirées des tests existants. Le Dr Jean-Sébastien Hulot (Mount Sinaï School of Medicine, New-York) et le Pr Pascale Gaussem (Hôpital Européen Georges Pompidou, Paris), font le point sur cette question.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

New Drug Could Reduce Blood Clots in Joint Replacement Patients

New Drug Could Reduce Blood Clots in Joint Replacement Patients | Veille Pharma | Scoop.it

Older patients who have hip or knee replacements could benefit from a new pill that lowers their risk of suffering potentially fatal blood clots.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

One Dose of Rivaroxaban After Low-Molecular-Weight Heparin Course Prevents Venous Thromboembolism: Presented at ACCP

HICAGO -- September 14, 2011 -- Initiation of 10 mg of oral rivaroxaban 12 to 24 hours after a final dose of low-molecular-weight heparin (LMWH) for prophylaxis of venous thromboembolism provides a prompt and predictable response that does not differ significantly from repeated doses of rivaroxaban, according to research presented here at the 40th Annual Meeting of the American College of Clinical Pharmacology (ACCP).

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ROCKET-AF rassurante pour les insuffisants rénaux sous rivaroxaban

Paris, France. Lors du congrès de l'European Society of cardiology, la session des clinical trials updates du dimanche 28 août 2011 a étudié la population des insuffisants rénaux modérés de l'étude ROCKET-AF, un thème important dans la mesure où la fonction/tolérance rénale est un aspect crucial de la prise en charge des patients fragiles. Dans la population des insuffisants rénaux modérés, les résultats de ROCKET-AF sont du même ordre que les conclusions générales de l'étude sur l'ensemble de l'effectif.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Medical News: ESC: Antidote to Factor Xa Inhibitors Shows Promise - in Meeting Coverage, ESC from MedPage Today

Medical News: ESC: Antidote to Factor Xa Inhibitors Shows Promise - in Meeting Coverage, ESC from MedPage Today | Veille Pharma | Scoop.it

PARIS -- Oral direct factor Xa inhibitors are an emerging class of drugs that are poised to take much of the market from warfarin on a wave of enthusiasm about their ease of use and reported safety, but, amid the hype, one fact remains: drugs like rivaroxaban (Xarelto) and apixaban (Eliquis) don't have an antidote.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Anti-Coagulant Blockbuster Drugs Are Here - Seeking Alpha

Introduction and Purpose of this Report
I believe that the anti-coagulant drug market is poised to become the next blockbuster category in cardiovascular disease, following the path of hypertension and cholesterol drugs. This could mean that sales would reach several billions of dollars arising from several individual blockbuster products. If I am correct, there is a significant commercial potential for three new anti-coagulant drugs that are in the early stages of commercial development.
more...
No comment yet.